|Bid||56.40 x 1400|
|Ask||56.60 x 1200|
|Day's Range||55.82 - 56.73|
|52 Week Range||55.82 - 69.75|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 04, 2022|
|Forward Dividend & Yield||1.96 (3.47%)|
|Ex-Dividend Date||Sep 30, 2021|
|1y Target Est||73.12|
Subscribe to Yahoo Finance Plus to view Fair Value for BMYLearn more
Although crashes are inevitable, they're the perfect time to buy great businesses at a discount.
NEW ORLEANS, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion
Buffett is taking profits off the table. It might be time to do the opposite.